{"type":"trials","record":{"id":42019,"source_id":"clinicaltrials-gov","external_id":"NCT04746963","title":"Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration","brief_summary":"This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.","overall_status":"Terminated","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"AsclepiX Therapeutics, Inc.","enrollment":3,"countries":["United States"],"start_date":"2021-02-01","completion_date":"2022-10-01","last_update_date":"2024-03-22","source_url":"https://clinicaltrials.gov/study/NCT04746963","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"SHASTA","age_range":"50 Years","comparator":null,"organization":"AsclepiX Therapeutics, Inc.","interventions":["AXT107 0.1 mg","AXT107 0.25 mg","AXT107 0.5 mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants Assessed by Incidence of Adverse Events (AEs) — Screening to Week 48"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Neovascular Age-Related Macular Degeneration (nAMD)","AXT107 0.1 mg","AXT107 0.25 mg","AXT107 0.5 mg"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04746963","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-02-01 to 2022-10-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.908Z","intervention":["AXT107 0.1 mg","AXT107 0.25 mg","AXT107 0.5 mg"],"participants":3,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants Assessed by Incidence of Adverse Events (AEs) — Screening to Week 48"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42019","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}